ASAP‐12 Score Predicts HBsAg Seroclearance and Seroconversion in Chronic Hepatitis B Patients Receiving Peg‐IFNα Add‐On Therapy
Journal of Medical Virology · 2025
DOI: 10.1002/jmv.70684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Jiayi Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B Surface Antigens, Interferon-alpha, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: This study was supported by National Natural Science Foundation of China (No. 82172254), 1.3.5 project for disciplines of excellence, West China Hospital, Sich…, National Natural Science Foundation of China.
Abstract (Originalsprache)
To develop new tools integrating host immune response and viral activity to predict Peg‐IFNα therapy efficiency in nucleos(t)ide analogs (NUCs)‐treated chronic hepatitis B (CHB) patients. This post‐hoc study analyzed data from 758 NUCs‐experienced, HBeAg‐negative CHB patients with baseline HBsAg < 1500 IU/mL and undetectable serum HBV DNA who completed 48 weeks of Peg‐IFNα add‐on therapy in a prospective study. Clinical and biochemical data were collected every 12 weeks and evaluated for their predictive value of HBsAg seroclearance and seroconversion. Age, qHBsAg, and ALT levels at Week 12 were associated with both HBsAg seroclearance and seroconversion. The ASAP‐12 score (ALT/[qHBsAg × Age] at Week 12), demonstrated strong discrimination for both endpoints (AUROCs: 0.802 [cut‐off 0.07] and 0.787 [cut‐off 0.12], respectively; p < 0.05). Patients with scores above the respective cut‐offs had significantly higher cumulative probabilities of HBsAg seroclearance (63.4% vs. 17.8%, Log‐rank test p < 0.001) and seroconversion (47.3% vs. 11.0%, Log‐rank test p < 0.001). Higher ASAP‐12 scores ( β = 0.206, p = 0.006) independently correlated with elevated Week 48 HBsAb levels. The ASAP‐12 score may serve as a useful tool to predict both HBsAg seroclearance and seroconversion at Week 48 of Peg‐IFNα add‐on therapy in NUCs‐experienced CHB patients, supporting individualized therapeutic decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
- Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
- Division of Infectious Diseases in State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China.
- Department of Infectious Diseases, People's Hospital of Deyang City, Deyang, Sichuan Province, China.
ORCID-Profile: Jiayi Wang, Hong Tang
Förderung
- This study was supported by National Natural Science Foundation of China (No. 82172254), 1.3.5 project for disciplines of excellence, West China Hospital, Sich…
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., Han, N., Bai, L., Li, H., Du, L., Liu, H., Zeng, Y., Zhang, H., Chen, X., Yang, J., Liao, J., He, M., Chen, H., Yan, L., & Tang, H. (2025). ASAP‐12 Score Predicts HBsAg Seroclearance and Seroconversion in Chronic Hepatitis B Patients Receiving Peg‐IFNα Add‐On Therapy. Journal of Medical Virology. https://doi.org/10.1002/jmv.70684
Vancouver
Wang J, Han N, Bai L, Li H, Du L, Liu H, et al. ASAP‐12 Score Predicts HBsAg Seroclearance and Seroconversion in Chronic Hepatitis B Patients Receiving Peg‐IFNα Add‐On Therapy. Journal of Medical Virology. 2025. doi:10.1002/jmv.70684
BibTeX
@article{Wang2025,
author = {Wang, Jiayi and Han, Ning and Bai, Lang and Li, Hong and Du, Lingyao and Liu, Huan and Zeng, Yilan and Zhang, Hong and Chen, Xuebing and Yang, Jiahong and Liao, Juan and He, Min and Chen, Han and Yan, Libo and Tang, Hong},
title = {ASAP‐12 Score Predicts HBsAg Seroclearance and Seroconversion in Chronic Hepatitis B Patients Receiving Peg‐IFNα Add‐On Therapy},
journal = {Journal of Medical Virology},
year = {2025},
doi = {10.1002/jmv.70684}
}
EUVIMED